Anti-TGF beta Receptor I antibody (ab31013)
Key features and details
- Rabbit polyclonal to TGF beta Receptor I
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-TGF beta Receptor I antibody
See all TGF beta Receptor I primary antibodies -
Description
Rabbit polyclonal to TGF beta Receptor I -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species WB Human
-
Immunogen
Synthetic peptide within Human TGF beta Receptor I aa 150-250. The exact sequence is proprietary.
Database link: P36897 -
Positive control
-
General notes
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.60
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab31013 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| WB |
Human
|
| All applications |
Mouse
Rat
Horse
Chicken
Cow
Pig
Xenopus laevis
|
| Application | Abreviews | Notes |
|---|---|---|
| WB | (14) |
Use at an assay dependent concentration. Predicted molecular weight: 56 kDa.
|
| Notes |
|---|
|
WB
Use at an assay dependent concentration. Predicted molecular weight: 56 kDa. |
Target
-
Function
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for TGF-beta. -
Tissue specificity
Found in all tissues examined, most abundant in placenta and least abundant in brain and heart. -
Involvement in disease
Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 1A (LDS1A) [MIM:609192]; also known as Furlong syndrome or Loeys-Dietz aortic aneurysm syndrome (LDAS). LDS1 is an aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by arterial tortuosity and aneurysms, craniosynostosis, hypertelorism, and bifid uvula or cleft palate. Other findings include exotropy, micrognathia and retrognathia, structural brain abnormalities, intellectual deficit, congenital heart disease, translucent skin, joint hyperlaxity and aneurysm with dissection throughout the arterial tree.
Defects in TGFBR1 are the cause of Loeys-Dietz syndrome type 2A (LDS2A) [MIM:608967]. LDS2 is an aortic aneurysm syndrome with widespread systemic involvement. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, diffuse arterial aneurysms and dissections, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. LDS2 is characterized by the absence of craniofacial abnormalities with the exception of bifid uvula that can be present in some patients.
Defects in TGFBR1 are the cause of aortic aneurysm familial thoracic type 5 (AAT5) [MIM:608967]. Aneurysms and dissections of the aorta usually result from degenerative changes in the aortic wall. Thoracic aortic aneurysms and dissections are primarily associated with a characteristic histologic appearance known as 'medial necrosis' in which there is degeneration and fragmentation of elastic fibers, loss of smooth muscle cells, and an accumulation of basophilic ground substance. -
Sequence similarities
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
Contains 1 GS domain.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated at basal levels in the absence of ligand binding. Activated by multiple phosphorylation, mainly in the GS region. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 282382 Cow
- Entrez Gene: 7046 Human
- Entrez Gene: 21812 Mouse
- Entrez Gene: 396665 Pig
- Entrez Gene: 29591 Rat
- Omim: 190181 Human
- SwissProt: O46680 Cow
- SwissProt: P36897 Human
see all -
Alternative names
- AAT 5 antibody
- AAT5 antibody
- Activin A receptor type II like kinase 53kDa antibody
see all
Images
-
Western blot - Anti-TGF beta Receptor I antibody (ab31013)Verified customerAll lanes :
Lane 1 : MCF7 (Human breast adenocarcinoma cell line) whole cell lysate withAnti-TGF beta Receptor I antibody (ab31013)
Lane 2 : A2780 (Human ovarian cancer cell line) whole cell lysate withAnti-TGF beta Receptor I antibody (ab31013)
Lysates/proteins at 20 µg per lane.
Blocking peptides at 1/1000 dilution per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab6721) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 56 kDa
Exposure time: 15 secondsPrimary antibody incubated for 15 hours at 4°C in TBST.
3% BSA used as blocking agent for 1 hour at 23°C.
-
Western blot - Anti-TGF beta Receptor I antibody (ab31013)This image is courtesy of an anonymous AbreviewAnti-TGF beta Receptor I antibody (ab31013) at 1/1000 dilution (for 18 hours at 4°C) + Mouse intestine whole tissue lysate at 15 µg
Secondary
An HRP-conjugated Goat anti-rabbit IgG polyclonal at 1/8000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 56 kDa
Observed band size: 56 kDa
Exposure time: 1 minuteBlocking Step: 5% milk for 1 hour at 4°C
-
Western blot - Anti-TGF beta Receptor I antibody (ab31013)Anti-TGF beta Receptor I antibody (ab31013) at 1 µg/ml + HepG2 (Human hepatocellular liver carcinoma cell line) whole cell lysate at 10 µg
Secondary
Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Predicted band size: 56 kDa
Observed band size: 56 kDa -
Western blot - Anti-TGF beta Receptor I antibody (ab31013)This image is courtesy of an anonymous AbreviewAnti-TGF beta Receptor I antibody (ab31013) at 1/750 dilution (for 16 hours at 4°C) + Rat intestine whole tissue lysate at 20 µg
Secondary
An HRP-conjugated Goat anti-rabbit IgG polyclonal at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 56 kDa
Observed band size: 56 kDa
Exposure time: 2 minutesBlocking Step: 5% milk for 1 hour at 20°C
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (133)
ab31013 has been referenced in 133 publications.
- Lai CC et al. Vitamin D Attenuates Loss of Endothelial Biomarker Expression in Cardio-Endothelial Cells. Int J Mol Sci 21:N/A (2020). PubMed: 32235811
- Huang Y et al. Overexpression of miR-133a-3p inhibits fibrosis and proliferation of keloid fibroblasts by regulating IRF5 to inhibit the TGF-ß/Smad2 pathway. Mol Cell Probes N/A:101563 (2020). PubMed: 32205184
- Lezmi G et al. Congenital cystic adenomatoid malformations of the lung: an epithelial transcriptomic approach. Respir Res 21:43 (2020). PubMed: 32019538
- Gao S et al. Nucleolar and Spindle Associated Protein 1 (NUSAP1) Promotes Bladder Cancer Progression Through the TGF-ß Signaling Pathway. Onco Targets Ther 13:813-825 (2020). PubMed: 32099387
- Romano GL et al. Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7. Sci Rep 10:3972 (2020). PubMed: 32132582